On March 15, 2018 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a
clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for patients with solid tumor cancers, reported that
preclinical data on its BET inhibitor CK-103 (also known as TG-1601) will be presented in a poster session
at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting to be held April 14 – 18, 2018, in
Chicago (Press release, Checkpoint Therapeutics, MAR 15, 2018, View Source [SID1234525089]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the poster presentation are as follows:

Title: TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in preclinical
models
Poster Session: Experimental and Molecular Therapeutics / Canonical Targets 2
Abstract Number: 5790
Poster Number: 16
Date and Time: Wednesday, April 18, 2018, 8 a.m. – 12 p.m. CDT
Location: McCormick Place South, Exhibit Hall A, Poster Section 36

Following the presentation, the poster will be available on the Publications page of the Pipeline section of
Checkpoint’s website, www.checkpointtx.com.

Additional information on the meeting can be found on the AACR (Free AACR Whitepaper) website www.aacr.org.